How is Cagrilintide administered?
This describes how Cagrilintide is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once weekly schedule, generally over open-ended. Specific dosing is individual and beyond general information, and human evidence for Cagrilintide is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once weekly
- Cycle length: Open-ended
- Half-life: ~7 days
References
- Once-weekly cagrilintide for weight management, Phase 2 trial — Lau DCW et al., Lancet, 2021
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) — Garvey et al., N Engl J Med, 2025
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial — Enebo et al., Lancet, 2021
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Cagrilintide
Full Cagrilintide breakdownCagrilintide what it's used forCagrilintide side effectsCagrilintide mistakes to avoidCagrilintide who should avoid itCagrilintide half-lifeCagrilintide how long to workCagrilintide legal statusCagrilintide how it workscagrilintide vs retatrutidesemaglutide vs cagrilintidetirzepatide vs cagrilintideAsk the AI Coach
Last updated 2026-06-15.